期刊: JOURNAL OF CLINICAL ONCOLOGY, 2021; 39 (8)
PURPOSE Mucosal melanoma (MM) is a highly vascularized tumor with an extremely poor prognosis. In this randomized, open-label, phase II study, we char......
期刊: JOURNAL OF CLINICAL ONCOLOGY, 2021; 39 (12)
PURPOSEPatients with the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) historically showed inferior survival with stand......
期刊: JOURNAL OF CLINICAL ONCOLOGY, 2021; 39 (9)
PURPOSE The role of maintenance therapy for gastric (GC) or gastroesophageal junction cancer (GEJC) is unclear. We investigated avelumab (anti-program......
期刊: JOURNAL OF CLINICAL ONCOLOGY, 2021; 39 (11)
PURPOSEGenetic rearrangements of the tyrosine receptor kinase ROS proto-oncogene 1 (ROS1) are oncogenic drivers in non-small-cell lung cancer (NSCLC).......
期刊: JOURNAL OF CLINICAL ONCOLOGY, 2021; 39 (10)
PURPOSE In relapsed and/or refractory multiple myeloma, daratumumab reduced the risk of progression or death by > 60% in POLLUX (daratumumab/lenali......
期刊: JOURNAL OF CLINICAL ONCOLOGY, 2021; 39 (6)
Purpose: Infant acute lymphoblastic leukemia (ALL) is characterized by a high incidence of KMT2A gene rearrangements and poor outcome. We evaluated th......
期刊: JOURNAL OF CLINICAL ONCOLOGY, 2021; 39 (7)
PURPOSE Effective interventions to improve prognosis in metastatic esophagogastric cancer (EGC) are urgently needed. We assessed the effect of the ear......
期刊: JOURNAL OF CLINICAL ONCOLOGY, 2021; 39 (7)
PURPOSE ADJUVANT-CTONG1104 (ClinicalTrials.gov identifier: NCT01405079), a randomized phase III trial, showed that adjuvant gefitinib treatment signif......